The first clinical trial exploring the SGLT2 inhibition effects on AD patients is ongoing and focuses on brain energy metabolism impact following therapy with the SGLT2 inhibitor dapagliflozin [111]. This evidence concerns the gene SLC5A2 and Alzheimer disease.